Profound Medical Corp. (PROF)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1628808 · fiscal year ends in Dec
Closing price $6.54 on 30 Oct 2026; 52-week range $5.06 to $8.65.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $19.1M
- Revenue growth
- 61.2%
- Net income, last twelve months
- -$32.7M
- Earnings per share
- $0.46
- Gross margin
- 71.8%
- Operating margin
- -185.3%
- Net margin
- -171.6%
- Return on equity
- -65.7%
- Market value
- $239.1M
- Price to earnings
- 14.2x
- Cash
- $38.3M
- Debt
- $4.5M
- Debt to equity
- 0.09
- Shares outstanding
- 36.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $16.1M | -$41.3M | -$42.6M | $1.41 | -$38.4M | 10-K filed 5 Mar 2026 |
| FY2024 | 31 Dec 2024 | $10.7M | -$33.1M | -$27.8M | $1.12 | – | 10-K filed 7 Mar 2025 |
| FY2023 | 31 Dec 2023 | $7.2M | -$28.7M | -$28.3M | $1.34 | – | 10-K filed 7 Mar 2025 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $2.5M | -$9.5M | -$0.26 |
| Q1 FY2026 | 31 Mar 2026 | $5.3M | -$7.1M | $0.19 |
| Q4 FY2025 | 31 Dec 2025 | $6.0M | -$8.2M | $0.27 |
| Q3 FY2025 | 30 Sep 2025 | $5.3M | -$8.0M | $0.26 |
| Q2 FY2025 | 30 Jun 2025 | $2.2M | -$15.7M | $0.52 |
| Q1 FY2025 | 31 Mar 2025 | $2.6M | -$10.7M | $0.36 |
| Q4 FY2024 | 31 Dec 2024 | $4.2M | -$4.9M | $0.20 |
| Q3 FY2024 | 30 Sep 2024 | $2.8M | -$9.4M | $0.38 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Recurring - non-capital | $9.7M | 60.4% |
| Capital equipment | $6.4M | 39.6% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $12.2M | 76.1% |
| Canada | $3.1M | 19.1% |
| Germany | $773.0K | 4.8% |
Company events
The newest 8-K filings of 47 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 22 Oct 2026 | 8-K | Investor update | 7.01, 9.01 |
| 14 Oct 2026 | 8-K | Investor update | 7.01, 9.01 |
| 9 Oct 2026 | 8-K | Investor update | 7.01, 9.01 |
| 7 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 3 Sep 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 17 Aug 2026 | 8-K | Investor update | 7.01, 9.01 |
| 17 Aug 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 13 Aug 2026 | 8-K | Investor update | 7.01, 9.01 |
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 24 Jul 2026 | 8-K | Investor update | 7.01, 9.01 |
| 16 Jul 2026 | 8-K | Investor update | 7.01, 9.01 |
Every filing
The newest filings with the SEC of 247 held.
| Filed | Form | Period |
|---|---|---|
| 22 Oct 2026 | 8-K | 22 Oct 2026 |
| 14 Oct 2026 | 8-K | 14 Oct 2026 |
| 9 Oct 2026 | 8-K | 9 Oct 2026 |
| 7 Oct 2026 | 8-K | 7 Oct 2026 |
| 4 Sep 2026 | 8-K | 3 Sep 2026 |
| 3 Sep 2026 | 8-K | 1 Sep 2026 |
| 17 Aug 2026 | 8-K | 17 Aug 2026 |
| 17 Aug 2026 | 8-K | 14 Aug 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 24 Jul 2026 | 8-K | 24 Jul 2026 |
Trades by members of the House
From each member's periodic transaction report.
| Traded | Member | Type | Amount | Disclosed |
|---|---|---|---|---|
| 14 Jan 2020 | Tom Malinowski (NJ07) | Purchase | $1,001 - $15,000 | 26 Aug 2021 |
| 27 Jan 2020 | Tom Malinowski (NJ07) | Purchase | $1,001 - $15,000 | 26 Aug 2021 |
| 20 Dec 2019 | Tom Malinowski (NJ07) | Purchase | $1,001 - $15,000 | 5 Mar 2021 |
| 21 Jul 2020 | Tom Malinowski (NJ07) | Purchase | $1,001 - $15,000 | 5 Mar 2021 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1.6M | +5.03% | 3.23 |
| 30 Sep 2026 | 1.5M | -5.61% | 11.89 |
| 15 Sep 2026 | 1.6M | -3% | 12.33 |
| 31 Aug 2026 | 1.6M | -12.01% | 14.47 |
| 14 Aug 2026 | 1.8M | +2.04% | 16.14 |
| 31 Jul 2026 | 1.8M | -2.56% | 14.66 |
| 15 Jul 2026 | 1.9M | -10.52% | 18.71 |
| 30 Jun 2026 | 2.1M | -3.52% | 35.06 |
Funds that hold it
From each fund's latest Form 13F.
60 funds held it at 30 Jun 2026: 16 added and 17 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| FIL Ltd | 2,370,000 | $15.8M | +30,000 |
| Gagnon Securities LLC | 1,960,074 | $13.0M | +15,750 |
| Royce & Associates LP | 1,199,564 | $8.0M | +83,216 |
| Timelo Investment Management Inc. | 1,114,967 | $7.4M | 0 |
| Gagnon Advisors, LLC | 962,186 | $6.4M | 0 |
| First Eagle Investment Management, LLC | 880,414 | $5.9M | – |
| Rosalind Advisors, Inc. | 828,118 | $5.5M | 0 |
| Z3 Capital Partners, LLC | 820,941 | $5.5M | +2,950 |
| Letko, Brosseau & Associates Inc. | 935,725 | $5.4M | -17,450 |
| Mmcap International Inc. SPC | 671,356 | $4.5M | -73,796 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B